Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED" per 10k dated 04/25/19.
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has "not yet" been dismissed.
Kinda odd imo that 230 - 240 million shares traded and there were BUYERS for all those shares. Maybe someone knew something was going to happen soon.
I think you are 100 percent correct. No one with any logic would sell 230 million shares from .0022 down to .014 for 11 days straight, especially when mydx has already said pen launch for summer unless they were forced to liquidate the shares. Any DD done shows multiple partners could be coming, makes absolutely no sense to sell here.
MYDX on it's way up!!!
MYDX at MEDMEN Headquarters. Quote 'MYDX it’s gonna be a great year'
https://www.instagram.com/p/BtMvBI8AbuB/
The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED" per 10k dated 04/25/19.
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has not yet been dismissed.
WOW: Powered by MYDX, Ganga Gold video now 236 views, from 3 views a couple days ago. Someones watching, views keep going up everyday..
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
Involvement in Legal Proceedings
To the Company’s knowledge, none of our officers or our directors has, during the last ten years:
?
been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
?
had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
?
been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;
?
been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
?
been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity;
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has "not yet" been dismissed.
In January of 2018, MyDx’s Biopharmaceutical division commenced clinical trials on its unique MyDx360 Pain Management Formula, appointed Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran to its Executive Advisory Board on April 24, 2018, secured city and state legal cannabis manufacturing and distribution for its MyDx360 customers in May 2018, and featured the Eco Smart Pen working Prototype on CFN Media in August 2018. The MyDx Analyzer was selected to be used in a large HIV Study by the University of Florida in September 2018. MyDx recruited Mr. Cannabis Group to operate the Company in November 2018, onboarding a new experienced CFO/CEO (Mr. Matthew Bucciero), a leading Harvard neuroscientist (Just Vincent) to its scientific advisory board, and Mr. Erai Beckmann, a seasoned cannabis industry professional, as a member of the Board.
SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.
“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”
We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.
This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.
Marijuana and Potential Long-term Effects Study Goals
The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.
The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.
During a visit, participants will be asked to:
Give a small blood sample
Give a small urine sample
Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad
The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).
The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.
The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit
PORTABLE DEVICE AND METHOD FOR VAPORIZING MATERIALS
Publication number: 20190014824
Abstract: A portable device, and more particularly a portable device for vaporizing materials such as oils for inhalation. Also, methods for vaporizing materials and methods of operating portable vaporizing devices. In addition, networks for providing operational features and/or instructions for operation of vaporizing devices and for monitoring and collecting operational data. In preferred embodiments, a vaporizing device and/or methods for operating a vaporizing device wherein the vaporizing device includes one or more of the following features: security features to regulate operation of the device; automatic detection of vaporizing material identity; user experience monitoring and data collection; and/or temperature adjustment of vaporizing material based on detected material for vaporization.
Type: Application
Filed: November 21, 2017
Publication date: January 17, 2019
Inventors: Daniel Yazbeck, Joshua Londano, James Panther, Jason Panther
https://patents.justia.com/inventor/daniel-yazbeck?fbclid=IwAR3UrUz5kPH_YRaYvRl7rF_rrk79Xuj1viP3-YG0c8h60_GAtkKg_KnEII4
IT'S COMING: MYDX Eco Smart Pen app picture: https://investorshub.advfn.com/uimage/uploads/2018/9/10/cssxwCOINS2.PNG
Is a picture worth a thousand words. How's this picture http://sharc-research.org/2018/10/16/sharc-student-andrew-fiore-to-use-portable-marijuana-analyzer-in-pilot-study/ showing a STUDENT AT UNIVERSITY OF FLORIDA holding a CannaDx tester with the quote of
'We are excited to share that student Andrew Fiore will be pursuing the use of the CannaDx sensor in a limited pilot study to evaluate the interest of marijuana analyzers in research participants!
This project highlights SHARC’s leading research that works to answer pressing questions about marijuana use. We are excited to see to follow Andrew’s progress.
The use of this device should not be viewed as an endorsement or validation of the CannaDx sensor by SHARC or the University of Florida'
But I guess non believers could say thats not a real person or not a real CannaDx tester in his hand.
Powered by MYDX, Ganga Gold video now 236 views, from 3 views a couple days ago. Someones watching, views keep going up everyday..
The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED" per 10k dated 04/25/19.
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has not yet been dismissed.
IT'S COMING: MYDX Eco Smart Pen app picture: https://investorshub.advfn.com/uimage/uploads/2018/9/10/cssxwCOINS2.PNG
PORTABLE DEVICE AND METHOD FOR VAPORIZING MATERIALS
Publication number: 20190014824
Abstract: A portable device, and more particularly a portable device for vaporizing materials such as oils for inhalation. Also, methods for vaporizing materials and methods of operating portable vaporizing devices. In addition, networks for providing operational features and/or instructions for operation of vaporizing devices and for monitoring and collecting operational data. In preferred embodiments, a vaporizing device and/or methods for operating a vaporizing device wherein the vaporizing device includes one or more of the following features: security features to regulate operation of the device; automatic detection of vaporizing material identity; user experience monitoring and data collection; and/or temperature adjustment of vaporizing material based on detected material for vaporization.
Type: Application
Filed: November 21, 2017
Publication date: January 17, 2019
Inventors: Daniel Yazbeck, Joshua Londano, James Panther, Jason Panther
https://patents.justia.com/inventor/daniel-yazbeck?fbclid=IwAR3UrUz5kPH_YRaYvRl7rF_rrk79Xuj1viP3-YG0c8h60_GAtkKg_KnEII4
MYDX still #4 out of 50 on the Most Posted Cannabis Stocks boards. I wonder why that is?? IT'S COMING. WOOHOO..
A bevy of businesses are striving to become the (already clichéd) “Amazon of cannabis,” and they are certainly assisting cannabis delivery and consumption. Whether it’s Dosist developing a dosing pen for various predefined purposes (e.g., with its “calm,” “bliss” and pain “relief” formulas), or MyDx offering a handheld chemical analyzer designed to instantly identify and measure chemicals and potency in a given sample, users are becoming better informed. Other companies are refining cannabis oils, tinctures, edibles and other products, and better crowdsourcing and databases will help identify and express cannabinoid effects to aid repeat and future customers in their decisions.
https://420intel.com/articles/2019/05/14/future-cannabis-trends-watch-out-0
Powered by MYDX, Ganga Gold video now 226 views, from 3 views a couple days ago. Someones watching.
In January of 2018, MyDx’s Biopharmaceutical division commenced clinical trials on its unique MyDx360 Pain Management Formula, appointed Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran to its Executive Advisory Board on April 24, 2018, secured city and state legal cannabis manufacturing and distribution for its MyDx360 customers in May 2018, and featured the Eco Smart Pen working Prototype on CFN Media in August 2018. The MyDx Analyzer was selected to be used in a large HIV Study by the University of Florida in September 2018. MyDx recruited Mr. Cannabis Group to operate the Company in November 2018, onboarding a new experienced CFO/CEO (Mr. Matthew Bucciero), a leading Harvard neuroscientist (Just Vincent) to its scientific advisory board, and Mr. Erai Beckmann, a seasoned cannabis industry professional, as a member of the Board
MYDX video for anyone that has not seen it, from 3 views to 226 now, all in a matter of days, someone's watching:
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
Involvement in Legal Proceedings
To the Company’s knowledge, none of our officers or our directors has, during the last ten years:
?
been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
?
had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
?
been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;
?
been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
?
been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity;
On January 26, 2018 the Company entered into a joint venture with Ganja Gold to form “NewCo”. With the formation of NewCo, the intent is for the Parties to manufacture and distribute a new premium line of physiological based Vape formulations under Ganja Gold Vape Brand (“GGV Brand”). The GGV Brand will be powered by MYDX data and formulations utilizing the Eco Smart Pen Device under an exclusive license of MYDX Power Formulations. MyDx will have the option to acquire 50% of NewCo. There was no activity in this joint venture during the year ended December 31, 2018.
SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.
“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”
We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.
This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.
Marijuana and Potential Long-term Effects Study Goals
The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.
The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.
During a visit, participants will be asked to:
Give a small blood sample
Give a small urine sample
Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad
The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).
The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.
The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has "not yet" been dismissed.
A bevy of businesses are striving to become the (already clichéd) “Amazon of cannabis,” and they are certainly assisting cannabis delivery and consumption. Whether it’s Dosist developing a dosing pen for various predefined purposes (e.g., with its “calm,” “bliss” and pain “relief” formulas), or MyDx offering a handheld chemical analyzer designed to instantly identify and measure chemicals and potency in a given sample, users are becoming better informed. Other companies are refining cannabis oils, tinctures, edibles and other products, and better crowdsourcing and databases will help identify and express cannabinoid effects to aid repeat and future customers in their decisions.
https://www.diego-pellicer.com/2019/05/14/trends-to-watch-out-for-•-high-times/
MyDx Commercial, Not sure if it's new but I have never seen it.
https://www.cannabisfn.com/cfnvideo/?id=l2iU4oOd
That's unusual, could be a good sign for today.
MYDX video for anyone that has not seen it, from 3 views to 221 now, all in a matter of days, someone's watching:
MYDX #4 on Cannabis Stocks Board, moving on up, we were #6 a couple of days ago.
MYDX LAWSUIT FILED: On July 14, 2017, the Company and its Chief Executive Officer, Daniel Yazbeck, filed a complaint in Superior Court of California against Jerome Dewald, Skip Sanzeri and twenty-five (25) persons or entities whose true identities are currently unknown to the Company (collectively, the “Defendants”). Mr. Sanzeri was the Chief Operating Officer of the Company in 2014 and 2015. The Defendants allegedly made false statements about the Company, its products, and Mr. Yazbeck on online investor platforms and at investor events.
The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED" per 10k dated 04/25/19.
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has not yet been dismissed.
From what I understand there are still 25, some named and some unnamed defendants still at large in the lawsuit. We'll wait for their court date to be published. It's coming just as sure as the ECO SMART PEN IS..
That's On July 14, 2017, the Company and its Chief Executive Officer, Daniel Yazbeck, filed a complaint in Superior Court of California against a series of Defendants who have allegedly engaged in unfair business practices, made false statements about the Company, its products, and Mr. Yazbeck at investor events and on online investor platforms.
Involvement in Legal Proceedings
To the Company’s knowledge, none of our officers or our directors has, during the last ten years:
?
been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
?
had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
?
been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;
?
been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
?
been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity;
On January 26, 2018 the Company entered into a joint venture with Ganja Gold to form “NewCo”. With the formation of NewCo, the intent is for the Parties to manufacture and distribute a new premium line of physiological based Vape formulations under Ganja Gold Vape Brand (“GGV Brand”). The GGV Brand will be powered by MYDX data and formulations utilizing the Eco Smart Pen Device under an exclusive license of MYDX Power Formulations. MyDx will have the option to acquire 50% of NewCo. There was no activity in this joint venture during the year ended December 31, 2018.